Global Leading Market Research Publisher QYResearch announces the release of its latest report “Biologics Identity Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Biologics Identity Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Biologics Identity Testing was estimated to be worth US$ 7391 million in 2025 and is projected to reach US$ 12750 million, growing at a CAGR of 8.2% from 2026 to 2032.
Biologics Identity Testing refers to the set of analytical methods and assays used to confirm the identity and authenticity of a biologic product (such as monoclonal antibodies, vaccines, cell or gene therapies, and recombinant proteins). The goal is to verify that the tested biologic is the correct product, with the expected molecular structure, sequence, and biological activity, and to distinguish it from other products, impurities, or contaminants.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096823/biologics-identity-testing
1. Industry Pain Points and the Shift Toward Comprehensive Identity Testing
Biologics—monoclonal antibodies, gene therapies, vaccines, and biosimilars—require rigorous identity confirmation to ensure product authenticity and patient safety. Unlike small-molecule drugs with simple chemical structures, biologics are complex macromolecules sensitive to manufacturing changes, potentially leading to product substitution, contamination, or loss of activity. Biologics identity testing addresses this through analytical methods (peptide mapping, mass spectrometry, ELISA, cell-based assays) that confirm molecular structure, sequence, and biological activity. For drug developers, CDMOs, and regulatory agencies, these tests are essential for regulatory compliance (FDA 21 CFR 610.14, ICH Q6B), product authentication, and distinguishing correct product from impurities or contaminants.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global biologics identity testing market was valued at US$ 7.391 billion in 2025 and is projected to reach US$ 12.750 billion by 2032, growing at a CAGR of 8.2%. Market growth is driven by three factors: expanding biologics pipeline (over 10,000 biologics in development), increasing biosimilar development (requiring extensive identity comparability studies), and stringent regulatory requirements for cell and gene therapies.
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- Biosimilar identity comparability: EMA and FDA accelerated biosimilar approvals (50+ approvals 2024-2025), requiring extensive analytical identity testing against reference products. Biosimilar segment grew 20% year-over-year.
- Gene therapy identity challenges: AAV capsid serotype confirmation and viral genome sequencing became critical for FDA IND submissions. Gene therapy identity testing grew 25% in 2025.
- High-throughput mass spectrometry: New LC-MS/MS platforms (Thermo Fisher, Charles River) reduced identity testing turnaround time from weeks to days.
- Chinese CRO expansion: Genscript Biotech and GL Biochem increased identity testing capacity by 30%, capturing Asia-Pacific market share.
4. Competitive Landscape and Key Suppliers
The market includes global CROs and specialized identity testing laboratories:
- Clean Cells (France), Charles River Laboratories (US), SGS SA (Switzerland), Eurofins Scientific (Luxembourg), BioAgilytix Labs (US), Genscript Biotech Corp. (China), AbbVie Inc. (US – internal testing), Rentschler Biopharma SE (Germany), Syngene International Ltd. (India), Thermo Fisher Scientific Inc. (US), GL Biochem Corp. (China), Abzena plc (UK).
Competition centers on three axes: analytical capabilities (mass spec, sequencing, immunoassays), regulatory expertise (FDA/EMA), and turnaround time.
5. Segment-by-Segment Analysis: Type and Application
By Service Type
- Method Development and Validation: (~45% of market). Developing identity tests for novel biologics (gene therapies, bispecific antibodies). Higher margin, longer timeline. Fastest-growing segment (CAGR 9%).
- Commercial Support Services: (~50% of market). Routine lot release testing for marketed biologics and biosimilars. High volume, recurring revenue.
- Others: Reference standard characterization, comparability studies. ~5% of market.
By End User
- Innovative Biologics Development: Largest segment (~50% of market). Novel mAbs, gene therapies, cell therapies.
- Biologics Development (biosimilars): (~30% of market). Extensive analytical similarity testing against reference products.
- Academic and Research Institutions: (~15% of market). Early-stage identity confirmation.
- Others: CDMOs, government labs. ~5% of market.
User case – Biosimilar identity comparability (mAb) : A biosimilar manufacturer outsourced identity testing to Charles River for a mAb candidate. Methods included peptide mapping (LC-MS), intact mass analysis, N-glycan profiling, and cell-based potency. All tests demonstrated analytical similarity to reference product (95-105% range), supporting FDA 351(k) submission.
6. Exclusive Insight: Identity Testing Methods Across Biologic Modalities
| Modality | Primary Identity Methods | Confirmatory Methods | Regulatory Guidance |
|---|---|---|---|
| Monoclonal antibody | Peptide mapping (LC-MS), intact mass | N-glycan profiling, disulfide mapping | ICH Q6B |
| Gene therapy (AAV) | Capsid serotype (ELISA), genome sequencing | ddPCR (identity), restriction mapping | FDA CGT guidance |
| Cell therapy (CAR-T) | Vector copy number (qPCR), CAR expression (flow) | Transduction efficiency | FDA CGT guidance |
| Vaccine (mRNA) | Sequencing (NGS), HPLC purity | capping efficiency (LC-MS) | ICH Q6B |
| Fusion protein | Peptide mapping, intact mass | Binding ELISA, cell-based potency | ICH Q6B |
Technical challenge: Confirming identity of gene therapy products (AAV) where capsid serotype and genome sequence must both match. AAV identity testing requires:
- Capsid ELISA (serotype-specific antibodies)
- Genome sequencing (NGS or Sanger)
- ddPCR (confirm serotype-specific ITR sequences)
- Restriction mapping (confirm genome integrity)
User case – AAV serotype misidentification: A gene therapy developer misidentified AAV serotype (claimed AAV9, actually AAV2) based on limited testing. Comprehensive identity testing (capsid ELISA + genome sequencing) revealed error, preventing clinical trial failure. Correct serotype used for subsequent manufacturing, saving US$ 10 million+ in potential write-offs.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (45% share, CAGR 8%). US (Charles River, Thermo Fisher, BioAgilytix, AbbVie). Strong biologics pipeline and regulatory framework.
- Europe: Second-largest (30% share, CAGR 8%). France (Clean Cells), Switzerland (SGS), Luxembourg (Eurofins), Germany (Rentschler), UK (Abzena). Strong biosimilar development.
- Asia-Pacific: Fastest-growing region (CAGR 9.5%). China (Genscript, GL Biochem), India (Syngene). Cost-effective CRO services.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The biologics identity testing market is positioned for strong growth through 2032, driven by biologics pipeline expansion, biosimilar development, and regulatory requirements. Stakeholders—from pharmaceutical companies to CROs—should prioritize high-resolution mass spectrometry for peptide mapping, capsid/genome testing for gene therapies, and method development expertise for novel modalities. By enabling product authentication and regulatory compliance, biologics identity testing is essential for biologic drug development and patient safety.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
